Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

ClinPharm Consulting Renamed to Kinetigen

Published: Thursday, February 07, 2013
Last Updated: Thursday, February 07, 2013
Bookmark and Share
Corporate name changed to establish a unique brand under Kinetigen.

ClinPharm Consulting, LLC (ClinPharm) has announced that the company is changing its name to Kinetigen, Inc., effective February 1, 2013.

All management, scientific, and operational components of Kinetigen remain the same as under ClinPharm, including the consulting firm’s focus on clinical pharmacology and pharmacokinetics.

The change to Kinetigen is a reflection of the impact that the company has made in the pharmaceutical industry and its evolution into a leading consulting firm in clinical pharmacology and pharmacokinetics.

In changing the company name, executive management determined that it was essential to develop a brand that will be easily identifiable and associated with the expertise and value that the company and its industry-leading consultants provide to clients.

“I’m thrilled to continue to build upon ClinPharm Consulting’s reputation and consultancy under our new name of Kinetigen” said Geoffrey Banks, Ph.D., Kinetigen President and CEO, adding, “The launch of Kinetigen is the keystone of our strategic growth initiative that will solidify our position as the go-to resource for clinical pharmacology and pharmacokinetics in the pharmaceutical industry”.

The consulting firm has grown organically over the past 5 years since the company was founded and recently added senior level consultants such as David Y. Mitchell, Ph.D., immediate past President of the American Association of Pharmaceutical Scientists (AAPS), Mark Sale, MD, former Global Director of Modeling and Simulation at GlaxoSmithKline (GSK), and Mark Bush, Ph.D., former Director of Pharmacokinetics at GSK.

“All of our services remain the same with the transition to Kinetigen,” said Bill Wargin, Ph.D., Kinetigen Executive Vice President & Chief Scientific Officer.

Dr. Wargin further explained “We have enhanced our SOPs and working practices, implemented more quality control procedures, and strengthened our training processes to ensure the highest quality product and services continue under Kinetigen that our clients have come to expect”.

Kinetigen’s services include:
• Rapid & robust pharmacokinetic analysis including non-compartmental, compartmental, and population pharmacokinetic methods with industry standard software (WinNonlin, NONMEM, Monolix, and NLME)
• Good Laboratory Practice (GLP) toxicokinetic analysis for determination of toxicokinetic parameters (including in-house QA capabilities and validated pharmacokinetic/ toxicokinetic analysis software)
• Unmatched interpretation of pharmacokinetic data from leading industry experts in pharmacokinetics
• Innovative model based drug development
• Clinical trial simulations
• Authoring clinical pharmacology and pharmacokinetic sections of regulatory submissions
• Assistance with regulatory briefing documents and meetings (e.g., FDA Pre-IND, EoP1, EoP2, pre-NDA, Type C meetings, etc.)
• Horizontal strategic planning across all phases of drug development
• Intelligent design of clinical studies from experts in clinical pharmacology and pharmacokinetics, including authoring clinical trial protocols and study reports
• Due diligence assessment for potential licensing of compounds

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos